Bio-Path (NASDAQ:BPTH) Earns Sell Rating from Analysts at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Bio-Path (NASDAQ:BPTH) in a research report issued on Monday. The brokerage set a “sell” rating on the stock.

Separately, Roth Mkm upped their target price on Bio-Path from $12.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, March 27th.

Bio-Path Price Performance

Bio-Path stock opened at $3.82 on Monday. The stock’s fifty day moving average is $6.28 and its two-hundred day moving average is $8.75. The stock has a market cap of $2.60 million, a PE ratio of -0.09 and a beta of 0.36. Bio-Path has a 1-year low of $3.51 and a 1-year high of $44.80.

Bio-Path (NASDAQ:BPTH) last announced its quarterly earnings results on Friday, March 8th. The company reported ($5.40) EPS for the quarter, hitting the consensus estimate of ($5.40). During the same quarter last year, the business earned ($10.60) EPS. On average, research analysts expect that Bio-Path will post -18.71 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Bio-Path

A number of institutional investors and hedge funds have recently made changes to their positions in BPTH. Walleye Capital LLC purchased a new position in shares of Bio-Path during the third quarter worth about $77,000. Vanguard Group Inc. raised its stake in Bio-Path by 77.5% during the 4th quarter. Vanguard Group Inc. now owns 270,029 shares of the company’s stock valued at $125,000 after acquiring an additional 117,914 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in Bio-Path during the 2nd quarter worth approximately $70,000. Citadel Advisors LLC purchased a new position in shares of Bio-Path in the 3rd quarter valued at approximately $35,000. Finally, Virtu Financial LLC acquired a new position in shares of Bio-Path in the first quarter valued at approximately $38,000. 5.74% of the stock is owned by hedge funds and other institutional investors.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.